1. Key Insights 2. Hepatocellular Carcinoma Market Overview at a Glance 2.1. Market Share (%) Distribution of Hepatocellular Carcinoma in 2017 2.2. Market Share (%) Distribution of Hepatocellular Carcinoma in 2028 3. Disease Background and Overview: Hepatocellular Carcinoma 3.1. Introduction 3.2. Signs and Symptoms 3.3. Staging of Hepatocellular Carcinoma 3.3.1. Okuda Stage 3.3.2. French Classification 3.3.3. CLIP Score 3.3.4. CUPI Score 3.3.5. TNM Stage 3.3.6. JIS Staging 3.3.7. BCLC Staging System 3.4. Etiology and Risk Factors 3.5. Pathophysiology 3.5.1. HCC progression and driver genes 3.5.2. Molecular Pathways involved in HCC 3.6. Diagnosis 3.7. Diagnostic Guidelines 3.7.1. American Association for the Study of Liver Diseases (AASLD) practice guidelines for HCC surveillance and diagnosis 3.7.2. European Association for the Study of the Liver (EASL)–European Organization for Research and Treatment of Cancer (EORTC) practice guidelines for HCC surveillance and diagnosis 3.7.3. Japanese evidence-based clinical practice guidelines for HCC 3.7.4. NCCN (National Comprehensive Cancer Network) Clinical practice Guidelines 4. Epidemiology and Patient Population 4.1. Key Findings 4.2. Population and Forecast Parameters 4.3. Total Diagnosed Incident Cases of HCC in 7MM 5. Country Wise-Epidemiology of HCC 5.1. The United States 5.1.1. Total Diagnosed Incident cases of HCC in the United States 5.1.2. Advance Stage Cases of HCC in the United States 5.1.3. Gender Specific Incident Cases of HCC in the United States 5.1.4. Incidence of HCC based on Aetiology in the United States 5.2. EU5 Countries 5.3. Germany 5.3.1. Total Diagnosed Incident cases of HCC in Germany 5.3.2. Advance Stage Cases of HCC in Germany 5.3.3. Gender Specific Incident Cases of HCC in Germany 5.3.4. Incidence of HCC based on Aetiology in Germany 5.4. France 5.4.1. Total Diagnosed Incident cases of HCC in France 5.4.2. Advance Stage Cases of HCC in France 5.4.3. Gender Specific Incident Cases of HCC in France 5.4.4. Incidence of HCC based on Aetiology in France 5.5. Italy 5.5.1. Total Diagnosed Incident cases of HCC in Italy 5.5.2. Advance Stage Cases of HCC in Italy 5.5.3. Gender Specific Incident Cases of HCC in Italy 5.5.4. Incidence of HCC based on Aetiology in Italy 5.6. Spain 5.6.1. Total Diagnosed Incident cases of HCC in Spain 5.6.2. Advance Stage Cases of HCC in Spain 5.6.3. Gender Specific Incident Cases of HCC in Spain 5.6.4. Incidence of HCC based on Aetiology in Spain 5.7. United Kingdom 5.7.1. Total Diagnosed Incident cases of HCC in the United Kingdom 5.7.2. Advance Stage Cases of HCC in the United Kingdom 5.7.3. Gender Specific Incident Cases of HCC in the United Kingdom 5.7.4. Incidence of HCC based on Aetiology in the United Kingdom 5.8. Japan 5.8.1. Total Diagnosed Incident cases of HCC in Japan 5.8.2. Advance Stage Cases of HCC in Japan 5.8.3. Gender Specific Incident Cases of HCC in Japan 5.8.4. Incidence of HCC based on Aetiology in Japan 6. Treatment Practices 6.1. Treatment Goals 6.2. Treatment Algorithm based on NCCN (National Comprehensive Cancer Network) Clinical Practice Guidelines for Treatment 6.3. AASLD Guidelines for the Treatment of Hepatocellular Carcinoma 6.3.1. Recommendations 6.4. Management guidelines for HCC: European Society for Medical Oncology (ESMO) 6.5. Management of Early and Intermediate HCC 6.6. Management of Advance Disease 6.7. Follow-up, long-term implications & survivorship 7. Unmet Needs 8. Organizations contributing towards HCC 9. Marketed Drug Analysis 9.1. Nexavar: Bayer HealthCare 9.1.1. Drug Description 9.1.2. Regulatory Milestones 9.1.3. Generic Availability 9.1.4. Clinical Development 9.1.5. Safety and Efficacy 9.1.6. Product Profile 9.2. Miripla: Sumitomo Dainippon Pharma 9.2.1. Drug Description 9.2.2. Regulatory Milestones 9.2.3. Clinical Development 9.2.4. Safety and Efficacy 9.2.5. Product Profile 9.3. Opdivo: Bristol-Myers Squibb 9.3.1. Drug Description 9.3.2. Regulatory Milestones 9.3.3. Clinical Development 9.3.4. Safety and Efficacy 9.3.5. Product Profile 9.4. Pembrolizumab (Keytruda): Merck & Co. 9.4.1. Drug Description 9.4.2. Regulatory Milestones 9.4.3. Clinical Development 9.4.4. Safety and Efficacy 9.4.5. Product Profile 9.5. Stivarga: Bayer Pharma 9.5.1. Drug Description 9.5.2. Regulatory Milestones 9.5.3. Generic Availability 9.5.4. Clinical Development 9.5.5. Safety and Efficacy 9.5.6. Product Profile 9.6. Ramucirumab (Cyramza): Eli Lilly and Co. 9.6.1. Product Description 9.6.2. Other Developmental Activities 9.6.3. Clinical Development 9.6.4. Safety and Efficacy 9.6.5. Product Profile 9.7. Cabometyx: Exelixis Inc. 9.7.1. Product Description 9.7.2. Other Developmental Activities 9.7.3. Clinical Development 9.7.4. Safety and Efficacy 9.7.5. Product Profile 9.8. Lenvima: Merck/Eisai 9.8.1. Drug Description 9.8.2. Regulatory Milestones 9.8.3. Clinical Development 9.8.4. Safety and Efficacy 9.8.5. Product Profile 10. Emerging Therapies 10.1. Emerging Drugs Analysis 10.1.1. Tislelizumab (BGB-A317): BeiGene 10.1.2. Durvalumab (Imfinzi): Astra Zeneca 10.1.3. Milciclib: Tiziana Life Sciences 10.2. Combinational Drugs Analysis 10.3. Failure in Phase III Clinical trials for Hepatocellular Carcinoma 11. Other Promising Candidates 11.1. Namodenoson (CF 102): Can-Fite BioPharma 11.1.1. Product Description 11.1.2. Other Developmental Activities 11.1.3. Clinical Development 11.1.4. Safety and Efficacy 11.1.5. Product Profile 11.2. Capmatinib: Eli Lilly and Co. 11.2.1. Product Description 11.2.2. Other Developmental Activities 11.2.3. Clinical Development 11.2.4. Safety and Efficacy 11.2.5. Product Profile 11.3. Palbociclib: Pfizer 11.3.1. Product Description 11.3.2. Clinical Development 11.3.3. Safety and Efficacy 11.3.4. Product Profile 11.4. ENMD2076: CASI Pharmaceuticals 11.4.1. Product Description 11.4.2. Other Developmental Activities 11.4.3. Clinical Development 11.4.4. Safety and Efficacy 11.4.5. Product Profile 11.5. HCC011: Tera Bio-Pharma 11.5.1. Product Description 11.5.2. Other Developmental Activities 11.5.3. Clinical Development 11.5.4. Product Profile 12. Case Studies 12.1. Unresectable Hepatocellular Carcinoma 12.2. Hepatocellular Carcinoma in a Young Adult 13. Hepatocellular Carcinoma [HCC]: 7MMMarket Analysis 13.1. Key Findings 13.2. Total Market Size of Hepatocellular Carcinoma (HCC) in 7MM 13.3. 7MM Market Size of HCC by Line of Therapies 14. Market Outlook by Country 14.1. The United States: Market Outlook 14.2. United States Market Size 14.2.1. Total Market size of Hepatocellular carcinoma [HCC] 14.2.2. Hepatocellular Carcinoma Market Size by Line of Therapies 14.2.3. Market Size by First Line of Therapies 14.2.4. Market Size by Second Line of Therapies 14.3. EU-5 Countries: Market Outlook 14.4. Germany Market Size 14.4.1. Total Market size of Hepatocellular Carcinoma 14.4.2. Hepatocellular Carcinoma Market Size by Line of Therapies 14.4.3. Market Size by First Line of Therapies 14.4.4. Market Size by Second Line of Therapies 14.5. France Market Size 14.5.1. Total Market size of Hepatocellular Carcinoma 14.5.2. Hepatocellular Carcinoma Market Size by Line of Therapies 14.5.3. Market Size by First Line of Therapies 14.5.4. Market Size by Second Line of Therapies 14.6. Italy Market Size 14.6.1. Total Market size of Hepatocellular Carcinoma 14.6.2. Hepatocellular Carcinoma Market Size by Line of Therapies 14.6.3. Market Size by First Line of Therapies 14.6.4. Market Size by Second Line of Therapies 14.7. Spain Market Size 14.7.1. Total Market size of Hepatocellular Carcinoma 14.7.2. Hepatocellular Carcinoma Market Size by Line of Therapies 14.7.3. Market Size by First Line of Therapies 14.7.4. Market Size by Second Line of Therapies 14.8. United Kingdom Market Size 14.8.1. Total Market size of Hepatocellular Carcinoma 14.8.2. Hepatocellular Carcinoma Market Size by Line of Therapies 14.8.3. Market Size by First Line of Therapies 14.8.4. Market Size by Second Line of Therapies 14.9. Japan: Market Outlook 14.9.1. Total Market size of Hepatocellular Carcinoma 14.9.2. Hepatocellular Carcinoma Market Size by Line of Therapies 14.9.3. Market Size by First Line of Therapies 14.9.4. Market Size by Second Line of Therapies 15. Market Drivers 16. Market Barriers 17. Appendix 18. Report Methodology 18.1. Sources Used 19. DelveInsight Capabilities 20. Disclaimer 21. About DelveInsight

Table 1: Staging systems along with the prognostic variables used in staging systems in Hepatocellular carcinoma Table 2: Risk factors and recommended surveillance for HCC according to etiology Table 3: Major recurrent molecular aberrations observed in advanced HCC Table 4: Total Incident Cases of HCC in 7MM (2017–2028) Table 5: Total Diagnosed Incident Cases of HCC in the United States (2017–2028) Table 6: Advance Stage Cases of HCC in the United States (2017–2028) Table 7: Gender Specific Incident Cases of HCC in the United States (2017–2028) Table 8: Incidence of HCC based on Aetiology in the United States (2017–2028) Table 9: Incidence of HCC by BCLC stages in the United States (2017–2028) Table 10: Total Diagnosed Incident Cases of HCC in Germany (2017–2028) Table 11: Advance Stage Cases of HCC in Germany (2017–2028) Table 12: Gender Specific Incident Cases of HCC in Germany (2017–2028) Table 13: Incidence of HCC based on Aetiology in Germany (2017–2028) Table 14: Incidence of HCC by BCLC stages in Germany (2017–2028) Table 15: Total Diagnosed Incident Cases of HCC in France (2017–2028) Table 16: Advance Stage Cases of HCC in France (2017–2028) Table 17: Gender Specific Incident Cases of HCC in France (2017–2028) Table 18: Incidence of HCC based on Aetiology in France (2017–2028) Table 19: Incidence of HCC by BCLC stages in France (2017–2028) Table 20: Total Diagnosed Incident Cases of HCC in Italy (2017–2028) Table 21: Advance Stage Cases of HCC in Italy (2017–2028) Table 22: Gender Specific Incident Cases of HCC in Italy (2017–2028) Table 23: Incidence of HCC based on Aetiology in Italy (2017–2028) Table 24: Incidence of HCC by BCLC stages in Italy (2017–2028) Table 25: Total Diagnosed Incident Cases of HCC in Spain (2017–2028) Table 26: Advance Stage Cases of HCC in Spain (2017–2028) Table 27: Gender Specific Incident Cases of HCC in Spain (2017–2028) Table 28: Incidence of HCC based on Aetiology in Spain (2017–2028) Table 29: Incidence of HCC by BCLC stages in Spain (2017–2028) Table 30: Total Diagnosed Incident Cases of HCC in the United Kingdom (2017–2028) Table 31: Advance Stage Cases of HCC in the United Kingdom (2017–2028) Table 32: Gender Specific Incident Cases of HCC in the United Kingdom (2017–2028) Table 33: Incidence of HCC based on Aetiology in the United Kingdom (2017–2028) Table 34: Incidence of HCC by BCLC stages in the United Kingdom (2017–2028) Table 35: Total Diagnosed Incident Cases of HCC in Japan (2017–2028) Table 36: Advance Stage Cases of HCC in Japan (2017–2028) Table 37: Gender Specific Incident Cases of HCC in Japan (2017–2028) Table 38: Incidence of HCC based on Aetiology in Japan (2017–2028) Table 39: Incidence of HCC by BCLC stages in Japan (2017–2028) Table 40: Organizations contributing toward Hepatocellular Carcinoma Table 41: Marketed Drug Analysis Table 42: Nexavar, Clinical Trial Description, 2019 Table 43: Miripla, Clinical Trial Description, 2019 Table 44: Opdivo Clinical Trial Description, 2019 Table 45: Keytruda Clinical Trial Description, 2019 Table 46: Regorafenib, Clinical Trial Description, 2019 Table 47: Ramucirumab, Clinical Trial Description, 2019 Table 48: Cabozantinib, Clinical Trial Description, 2019 Table 49: Lenvima, Clinical Trial Description, 2019 Table 50: Emerging Drugs Analysis Table 51: BGB-A317, Clinical Trial Description, 2019 Table 52: Durvalumab, Clinical Trial Description, 2019 Table 53: Milciclib, Clinical Trial Description, 2019 Table 54: Combinational Drug Analysis Table 55: Clinical Trial Description, 2019 Table 56: CF-102, Clinical Trial Description, 2019 Table 57: INC280, Clinical Trial Description, 2019 Table 58: PD-0332991, Clinical Trial Description, 2018 Table 59: ENMD2076, Clinical Trial Description, 2019 Table 60: 7MM Market Size of HCC in USD Million (2017–2028) Table 61: 7MM HCC Market Size by Line of therapies in USD Million (2017–2028) Table 62: The US Market Hepatocellular Carcinoma in USD Million (2017–2028) Table 63: The U.S. HCC Market Size by Line of therapies in USD Million (2017–2028) Table 64: The US HCC market size by First Line of Therapies in USD Million (2017–2028) Table 65: The US HCC market size by Second Line of Therapies in USD Million (2017–2028) Table 66: Germany Market Hepatocellular Carcinoma in USD Million (2017–2028) Table 67: Germany HCC Market Size by Line of therapies in USD Million (2017–2028) Table 68: Germany HCC market size by First Line of Therapies in USD Million (2017–2028) Table 69: Germany HCC market size by Second Line of Therapies in USD Million (2017–2028) Table 70: France Market Hepatocellular Carcinoma in USD Million (2017–2028) Table 71: France HCC Market Size by Line of therapies in USD Million (2017–2028) Table 72: France HCC market size by First Line of Therapies in USD Million (2017–2028) Table 73: The France HCC market size by Second Line of Therapies in USD Million (2017–2028) Table 74: The Italy Market Hepatocellular Carcinoma in USD Million (2017–2028) Table 75: Italy HCC Market Size by Line of therapies in USD Million (2017–2028) Table 76: Italy HCC market size by First Line of Therapies in USD Million (2017–2028) Table 77: The Italy HCC market size by Second Line of Therapies in USD Million (2017–2028) Table 78: The Spain Market Hepatocellular Carcinoma in USD Million (2017–2028) Table 79: Spain HCC Market Size by Line of therapies in USD Million (2017–2028) Table 80: Spain HCC market size by First Line of Therapies in USD Million (2017–2028) Table 81: Spain HCC market size by Second Line of Therapies in USD Million (2017–2028) Table 82: The UK Market Hepatocellular Carcinoma in USD Million (2017–2028) Table 83: UK HCC Market Size by Line of therapies in USD Million (2017–2028) Table 84: The UK HCC market size by First Line of Therapies in USD Million (2017–2028) Table 85: The UK HCC market size by Second Line of Therapies in USD Million (2017–2028) Table 86: The Japan Market Hepatocellular Carcinoma in USD Million (2017–2028) Table 87: Japan HCC Market Size by Line of therapies in USD Million (2017–2028) Table 88: Japan HCC market size by First Line of Therapies in USD Million (2017–2028) Table 89: The Japan HCC market size by Second Line of Therapies in USD Million (2017–2028) Figure 1: BCLC staging system and therapeutic strategy Figure 2: HCC progression and driver genes Figure 3: Molecular targeted therapies for HCC and their target Signaling pathways Figure 4: PD1 & PD-L1 Signaling pathway Figure 5: PD-1/PD-L1 Met pathway Figure 6: FGFR pathway Figure 7: FGFR pathway in Tumor proliferation & apoptosis Figure 8: HGF/cMET Pathway in HCC Figure 9: Multi-receptor Pathway in HCC Figure 10: List of Biomarkers for HCC & Liver Cirrhosis Figure 11: List of Biomarkers for HCV & HCB related HCC Figure 12: List of Prognostic & Diagnostic Biomarkers for HCC in Blood Figure 13: List of Prognostic & Diagnostic Biomarkers for HCC in Blood Figure 14: AASLD practice guidelines for HCC surveillance and diagnosis Figure 15: EASL-EORTC practice guidelines for HCC surveillance and diagnosis Figure 16: Japanese evidence-based clinical practice guidelines for HCC: surveillance and diagnostic algorithm Figure 17:NCCN (National Comprehensive Cancer Network) Clinical practice Guidelines for Diagnosis Figure 18:NCCN Clinical practice Guidelines – When HCC is confirmed (continued from figure 7) Figure 19: Total Diagnosed Incident Cases of HCC in 7MM (2017–2028) Figure 20: Total Diagnosed Incident Cases of HCC in the United States (2017–2028) Figure21: Advance Stage Cases of HCC in the United States (2017–2028) Figure 22: Gender Specific Incident Cases of HCC in the United States (2017–2028) Figure 23: Incidence of HCC based on Aetiology in the United States (2017–2028) Figure 24: Incidence of HCC by BCLC stages in the United States (2017–2028) Figure 25: Total Diagnosed Incident Cases of HCC in Germany (2017–2028) Figure26: Advance Stage Cases of HCC in Germany (2017–2028) Figure 27: Gender Specific Incident Cases of HCC in Germany (2017–2028) Figure 28: Incidence of HCC based on Aetiology in Germany (2017–2028) Figure 29: Incidence of HCC by BCLC stages in Germany (2017–2028) Figure 30: Total Diagnosed Incident Cases of HCC in France (2017–2028) Figure31: Advance Stage Cases of HCC in France (2017–2028) Figure 32: Gender Specific Incident Cases of HCC in France (2017–2028) Figure 33: Incidence of HCC based on Aetiology in France (2017–2028) Figure 34: Incidence of HCC by BCLC stages in France (2017–2028) Figure 35: Total Diagnosed Incident Cases of HCC in Italy (2017–2028) Figure36: Advance Stage Cases of HCC in Italy (2017–2028) Figure 37: Gender Specific Incident Cases of HCC in Italy (2017–2028) Figure 38: Incidence of HCC based on Aetiology in Italy (2017–2028) Figure 39: Incidence of HCC by BCLC stages in Italy (2017–2028) Figure 40: Total Diagnosed Incident Cases of HCC in Spain (2017–2028) Figure41: Advance Stage Cases of HCC in Spain (2017–2028) Figure 42: Gender Specific Incident Cases of HCC in Spain (2017–2028) Figure 43: Incidence of HCC based on Aetiology in Spain (2017–2028) Figure 44: Incidence of HCC by BCLC stages in Spain (2017–2028) Figure 45: Total Diagnosed Incident Cases of HCC in the United Kingdom (2017–2028) Figure46: Advance Stage Cases of HCC in the United Kingdom (2017–2028) Figure 47: Gender Specific Incident Cases of HCC in the United Kingdom (2017–2028) Figure 48: Incidence of HCC based on Aetiology in the United Kingdom (2017–2028) Figure 49: Incidence of HCC by BCLC stages in the United Kingdom (2017–2028) Figure 50: Total Diagnosed Incident Cases of HCC in Japan (2017–2028) Figure51: Advance Stage Cases of HCC in Japan (2017–2028) Figure 52: Gender Specific Incident Cases of HCC in Japan (2017–2028) Figure 53: Incidence of HCC based on Aetiology in Japan (2017–2028) Figure 54: Incidence of HCC by BCLC stages in Japan (2017–2028) Figure 55:NCCN (National Comprehensive Cancer Network) Clinical practice Guidelines for Diagnosis Figure 56: Treatment algorithm according to NCC guidelines Figure 57: Unmet Needs for Hepatocellular Carcinoma Figure 58: 7MM Market Size of HCC in USD Million (2017–2028) Figure 59: 7MM Market Size of HCC by Line of Therapies in USD Million (2017–2028) Figure 60: Market Size of HCC in the United States, USD Millions (2017–2028) Figure 61: The U.S. HCC Market Size by Line of therapies in USD Million (2017–2028) Figure 62: The U.S. market size of HCC by First Line of therapies in USD Million (2017–2028) Figure 63: The U.S. market size of HCC by Second Line of therapies in USD Million (2017–2028) Figure 64: Market Size of HCC in the Germany, USD Millions (2017–2028) Figure 65: Germany HCC Market Size by Line of therapies in USD Million (2017–2028) Figure 66: Germany market size of HCC by First Line of therapies in USD Million (2017–2028) Figure 67: Germany market size of HCC by Second Line of therapies in USD Million (2017–2028) Figure 68: Market Size of HCC in France, USD Millions (2017–2028) Figure 69: France HCC Market Size by Line of therapies in USD Million (2017–2028) Figure 70: France market size of HCC by First Line of therapies in USD Million (2017–2028) Figure 71: The France market size of HCC by Second Line of therapies in USD Million (2017–2028) Figure 72: Market Size of HCC in Italy, USD Millions (2017–2028) Figure 73: The Italy HCC Market Size by Line of therapies in USD Million (2017–2028) Figure 74: The Italy market size of HCC by First Line of therapies in USD Million (2017–2028) Figure 75: The Italy market size of HCC by Second Line of therapies in USD Million (2017–2028) Figure 76: Market Size of HCC in Spain, USD Millions (2017–2028) Figure 77: The Spain HCC Market Size by Line of therapies in USD Million (2017–2028) Figure 78: Spain market size of HCC by First Line of therapies in USD Million (2017–2028) Figure 79: Spain market size of HCC by Second Line of therapies in USD Million (2017–2028) Figure 80: Market Size of HCC in UK, USD Millions (2017–2028) Figure 81: The UK HCC Market Size by Line of therapies in USD Million (2017–2028) Figure 82: The UK market size of HCC by First Line of therapies in USD Million (2017–2028) Figure 83: The UK market size of HCC by Second Line of therapies in USD Million (2017–2028) Figure 84: Market Size of HCC in Japan, USD Millions (2017–2028) Figure 85: The Japan HCC Market Size by Line of therapies in USD Million (2017–2028) Figure 86: Japan market size of HCC by First Line of therapies in USD Million (2017–2028) Figure 87: Japan market size of HCC by Second Line of therapies in USD Million (2017–2028) Figure 88: Market Drivers for Hepatocellular Carcinoma Figure 89: Market Barriers for Hepatocellular Carcinoma

• Bayer HealthCare • Sumitomo Dainippon Pharma • Bristol-Myers Squibb • Merck & Co. • Bayer Pharma • Eli Lilly and Co. • Exelixis Inc. • Merck • Eisai